Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9531867 | 0.80 | CHRM2 (0.33) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16737003 | 0.75 | GPX4 (0.34) | RAB9ANPC1KDM4EALDH1A1POLB | |
| SCHEMBL1286161 | 0.73 | KDM4E (0.32) | PPM1BRAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL12254772 | 0.72 | HMGCR (0.36) | SMN1; SMN2KDM4EALDH1A1TP53CHRM1 | |
| SCHEMBL6104114 | 0.72 | — | — | |
| SCHEMBL21500160 | 0.69 | KDM4E (0.41) | PPM1BRAB9ASMN1; SMN2KDM4ETP53 | |
| SCHEMBL14236960 | 0.69 | ALDH1A1 (0.32) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5192078 | 0.69 | — | — | |
| SCHEMBL14838639 | 0.69 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL13170572 | 0.68 | KMT2A (0.37) | SMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795370-B2 | Tetracarboxylic acid compound, polyimide thereof, and production method thereof | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20090182114-A1 | TETRACARBOXYLIC ACID COMPOUND, POLYIMIDE THEREOF, AND PRODUCTION METHOD THEREOF | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182114-A1 | TETRACARBOXYLIC ACID COMPOUND, POLYIMIDE THEREOF, AND PRODUCTION METHOD THEREOF | CA1, TTC14, F12 | PPM1B 4203/4885RAB9A 2963/4885NPC1 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.